ArticleVeterinary surgery : VS2026
Short- and long-term outcome and quality of life assessment in dogs undergoing transvenous coil embolization of congenital intrahepatic portosystemic shunts.
Article in Veterinary surgery : VS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate short- and long-term outcomes and health-related quality of life (Hr-QoL) in dogs with congenital intrahepatic portosystemic shunts (cIHPSS) treated using percutaneous transcatheter embolization (PTCE). STUDY
designSingle center retrospective and prospective study. ANIMALS: Sixty-one client-owned dogs.
methodsMedical records were reviewed, and owners completed validated Hr-QoL and congenital portosystemic shunt scoring (Hr-CPSS) questionnaires. Hr-QoL scores ranged from 0 (worst) to 100 (best), and Hr-CPSS from 0 (best) to 100 (worst). Survival was assessed using Kaplan-Meier analysis. Medical or dietary management at final follow-up were recorded.
resultsMedian follow-up time was 769 days (interquartile range [IQR]: 297-1865). Median survival time was 1496 days. At last follow-up, 33 of 59 dogs remained on medical management and/or a specialized diet. Median Hr-CPSS significantly decreased from prediagnosis (25 [IQR: 18-51.3]) to post-PTCE (5 [IQR: 3-11]; p < .001), but not between post-medical and post-PTCE (p = .68). Median Hr-QoL scores improved post-PTCE (100 [IQR: 80-100]) compared to prediagnosis (35 [IQR: 10-50], p < .0001), and post-medical (75 [IQR: 40-90], p = .005) as well as between prediagnosis and post-medical (p = .038). One-, two-, and five-year survival rates were 83%, 66%, and 54%, respectively.
conclusionTreatment of cIHPSS with PTCE in dogs was associated with a good long-term survival and significant improvement in QoL and clinical signs. IMPACT: The combination of PTCE and targeted medical management provides an effective minimally invasive treatment option for dogs with cIHPSS, supporting improved longevity and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.